Adrenal corticosteroid inhibitor drugs prevent the adrenal cortex from producing biosynthesis of hormones such as androgen, estrogen, glucocorticoids, and mineralocorticoids. In the steroid synthesis pathway, one or more enzymes are blocked by the adrenal corticosteroid inhibitor drugs. These drugs are used for the treatment of prostate cancer, Cushing's syndrome, and breast cancer. Adrenal corticosteroid inhibitor drugs are also used as diagnostic tools to determine the cause of an illness or disorder such as in procedures to check pituitary function. They affect steroid production and are used for the treatment of cancer or tumor of adrenal cortex and also to check pituitary gland's function. The adrenal corticosteroid inhibitor drugs are also used when the adrenal cortex is overactive and not leading to cancer. Prostate cancer is the formation of a malignant tumor inside the prostate gland. In Cushing's syndrome, there is an increased concentration of glucocorticoid hormone. Glucocorticoid hormone affects all the tissues and organs of the body. In breast cancer, there is a malignant growth that begins in the tissues of breasts.
Increase in prevalence of prostate cancer is driving the global adrenal corticosteroid inhibitor drugs market. According to the World Cancer Research Fund International, in 2012, more than 1.1 million cases of prostate cancer were recorded which accounted for approximately 15% cases in men and approximately 8% of total new cases. Furthermore, rise in prevalence of Cushing’s syndrome boosts the demand for the adrenal corticosteroid inhibitor drugs. According to the American Association of Neurological Surgeons, approximately 10 to 15 people in a million are affected by Cushing’s syndrome every year. Increase in prevalence of breast cancer across the world, including developed as well as under-developed countries, drives the global adrenal corticosteroid inhibitor drugs market. According to the World Health Organization, 58% of deaths caused by breast cancer occur in under-developed or developing countries in the world. However, reduced awareness regarding the adrenal corticosteroid inhibitor drugs restrains the global adrenal corticosteroid inhibitor drugs market to an extent. There are only a few key players operating in the global adrenal corticosteroid inhibitor drugs market, thereby creating opportunities for new players to enter the market.
The global adrenal corticosteroid inhibitor drugs market can be segmented on the basis of dosage form, active ingredient type, disease type, distribution channel, and region. In terms of dosage form, the adrenal corticosteroid inhibitor drugs market can be divided into tablets and capsules. Based on active ingredient type, the adrenal corticosteroid inhibitor drugs market can be categorized into aminoglutethimide and metyrapone. In terms of disease type, the adrenal corticosteroid inhibitor drugs market can be classified into prostate cancer, Cushing's syndrome, and breast cancer, while by distribution channel, the market can be divided into the online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the adrenal corticosteroid inhibitor drugs market can be divided into Europe, Asia Pacific, Latin America, North America, and Middle East & Africa. North America accounted for the leading share of the adrenal corticosteroid inhibitor drugs market in 2016 owing to rise in prevalence of prostate and breast cancer. Europe constituted the next leading share of the adrenal corticosteroid inhibitor drugs market in 2016 and is expected to expand during the forecast period. According to the World Health Organization, 89.7 in 100,000 women are suffering from breast cancer in Western Europe. The adrenal corticosteroid inhibitor drugs market in Asia Pacific is anticipated to expand during the forecast period due to rise in prevalence of breast cancer, prostate cancer, and Cushing's syndrome in the region. The adrenal corticosteroid inhibitor drugs market in Middle East & Africa is anticipated to expand during the forecast period owing to increase in awareness regarding adrenal corticosteroid inhibitor drugs. The adrenal corticosteroid inhibitor drugs market in Latin America looks promising during the forecast period.
Key players of global adrenal corticosteroid inhibitor drugs market include Novartis AG and HRA Pharma.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.